Acadia pharmaceuticals reports third quarter 2025 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced its financial results for the third quarter ended september 30, 2025. “acadia delivered another strong quarter, generating total revenue of $278.6 million,” said catherine owen adams, chief executive officer. “nuplazid achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. daybue delivered $101.1 million in sales, driven by the expansion o.
ACAD Ratings Summary
ACAD Quant Ranking